Irvine-based Allergan Inc. said Thursday it has partnered with Sirna Therapeutics Inc. to develop treatments for age-related blindness.
San Francisco-based Sirna is set to get $5 million upfront and as much as $245 million based on future sales of treatments based on its Sirna-027 compound.
Allergan will be responsible for developing and commercializing the treatments used to treat eye diseases. The partnership also plans to use Allergan’s eye drug delivery technologies to treat patients.
The companies plan to form a committee to oversee the partnership.
